EX-10.17 3 a15-23151_1ex10d17.htm EX-10.17 CONFIDENTIAL TREATMENT REQUESTED November 30, 2015 Via Email Jennifer Low, M.D., Ph.D., M.H.Sc. Re: Terms of Transition and Separation Dear Dr. Low:Terms of Transition and Separation • May 5th, 2020 • California
Contract Type FiledMay 5th, 2020 JurisdictionThis letter confirms the agreement (“Agreement”) between you and Loxo Oncology, Inc. (the “Company”) concerning the terms of your transition and separation from employment and offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision of a general release of claims and covenant not to sue now and upon the Separation Date (defined below) as provided herein. If you agree to the terms outlined herein, please sign and return this Agreement to me in the timeframe outlined below.
February 1, 2013Terms of Transition and Separation • February 4th, 2013 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Washington
Contract Type FiledFebruary 4th, 2013 Company Industry JurisdictionThis letter confirms the agreement (“Agreement”) between you and OncoGenex Pharmaceuticals, Inc. (the “Company”) concerning the terms of your transition and separation from employment and offers you certain benefits in exchange for a general release of claims and covenant not to sue upon termination of your employment and upon the termination of the Consultancy (as defined below), as provided in further detail below. If you agree to abide by the terms outlined in this letter, please sign and return this letter to me no later than February 1, 2013.